Prosaikogenin A is primarily studied for its potential anti-inflammatory and neuroprotective effects. It has shown promise in modulating pathways involved in neuronal cell survival, making it a candidate for research in neurodegenerative conditions such as Alzheimer's and Parkinson’s disease. The compound exhibits activity in reducing oxidative stress and inhibiting pro-inflammatory cytokines, which may contribute to its therapeutic potential in chronic inflammatory diseases. Additionally, it has been investigated for its role in promoting nerve regeneration and synaptic plasticity, suggesting possible applications in treating nerve injury or cognitive disorders. Furthermore, studies have explored its anti-cancer properties, particularly in inhibiting the growth of certain cancer cell types, positioning it as a promising lead compound for developing new therapeutic agents. Most studies remain in the preclinical stage, focusing on in vitro and animal models to evaluate efficacy and mechanism of action.